Xeris Biopharma Revenue Rises 44%, Raises 2026 Guidance
Xeris reported third-quarter 2026 revenue of $107 million, up 44% year over year. Recorlev net revenue grew 93% to more than $71 million. The company raised its 2026 revenue guidance to $395 million–$405 million and its 2030 outlook to more than $1 billion, from approximately $750 million.
Xeris Biopharma reported total revenue of $107 million for the third quarter of 2026, a 44% increase compared to the same period last year. Net revenue for its product Recorlev grew 93% year-over-year to over $71 million. Driven by this performance, the company raised its full-year 2026 total revenue guidance to a range of $395 million to $405 million. Additionally, Xeris increased its 2030 total revenue outlook to more than $1 billion, up from a previous estimate of approximately $750 million.
Management attributed the growth to the successful expansion of its commercial team and increased patient starts.